ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: This systematic review and meta-analysis examines the relative risk of hepatotoxicity of new-generation BCR-ABL fusion oncoprotein tyrosine kinase inhibitors (TKIs) vs imatinib among patients with chronic myeloid leukemia.